The South Africa Pharmaceuticals and Healthcare Report

    • Independent 5-year pharmaceutical and healthcare industry forecasts for South Africa.
    • Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the South African pharmaceutical and healthcare industry.
    • Competitive intelligence, South African pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the South African market.

The South Africa Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2012 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s South Africa Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the South African pharmaceutical and healthcare industry.

" “I subscribe to BMI’s South Africa Pharmaceuticals & Healthcare Report, and have a high opinion of BMI publications. They are usually crisp and objective. ” "
Dr Vikash Salig (MB.ChB; MBA), CEO Dr Reddy’s Laboratories (Pty) Ltd, South Africa

Key Benefits of Report

    • Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on South Africa to test other views – a key input for successful budgeting and strategic business planning in the South African pharmaceutical and healthcare market.
    • Target Business Opportunities & Risks in the South African Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in South Africa.
    • Exploit The Latest Competitive South African Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in South Africa.

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

  • Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
  • Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
  • OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
  • Generics market (US$bn)/ as % of total market
  • Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

Executive Summary

[TOP]

Executive Summary

South Africa has one of the most developed pharmaceutical markets in the Middle East and Africa (MEA) region – only Turkey's market is larger. Pharmaceutical spending was US$3.08bn in 2006, and BMI forecasts this will rise to US$4.62bn by 2011.

Market growth will be hampered by a series of cost-containment measures introduced by the government. Authorities plans to draw up a National Health Reference Price List, which will increase transparency in the private health sector. However, many in the industry see this as a way for the government to exert downward pressure on pharmaceutical prices.

Demand for antiretrovirals (ARVs) will remain high due to the country's position at the centre of Africa's HIV/AIDS pandemic. However, funding for drugs will remain a problem, since the majority of patients have low incomes, so are reliant on state-healthcare.

The government is due to announce a new ARV tender in Q108, something that has already seen local manufacturers jockeying for position. Rapidly growing Enaleni Pharmaceuticals will be hoping for a large slice of the contract. As will Adcock Ingram – in the process of being decoupled from the Tiger Brands Group – which launched its own range of branded-generic ARVs earlier this year.

South Africa became the first developing country to join the Pharmaceutical Inspection Convention and Co-operation Scheme (PIC/S) in July, which sets out stringent good manufacturing practice (GMP) guidelines. Most multinationals operating in South Africa already comply with the scheme. However, a number of local drug makers, including Enaleni are not yet up to standard. Enaleni chose to close its main manufacturing plant for two months between July and September to speed up the upgrade.

South Africa remains in joint sixth position in BMI's updated MEA Business Environment Rankings for Q307. The country benefits from a relatively stable political climate and large market size. However, its limited potential for growth, and strong domestic manufacturing sector, which includes Aspen Pharmacare, one of the world's top-20 generic manufacturers, serve to hold down the market's score.

Contents

[TOP]

Chapter 1 - Executive Summary

South Africa Economic SWOT

South Africa Business Environment SWOT

Chapter 2 - South Africa: Business Environment Ranking

Table: Business Environment Ranking: Middle East & Africa

Business Environment Ranking

Economics – Long-Term Risk

Politics – Long-Term Risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - South Africa: Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property Environment

Pricing & Reimbursement Issues

Chapter 5 - Industry Developments

Healthcare Sector

HIV/AIDS

Tuberculosis

Pharmaceutical Sector

Table: PIASA Membership

Company Developments

Table: Results Of South Africa HIV/AIDS Drug Tender, March 2005

Chapter 6 - Industry Forecast Scenario

Overall Market Forecast

Table: South Africa Drug Market Forecast Indicators

Key Growth Factors – Industry

Table: Health Expenditure Indicators

Prescription & OTC Market Forecasts

Table: South Africa Prescription Drug Market Forecast Indicators

Table: South Africa OTC Drug Market Forecast Indicators 2004-2010

Generics Market Forecast

Table: Generic & Branded Drugs Forecasts

Export/Import Forecasts

Table: South Africa Export & Import Trade Forecast Indicators

Key Risks To BMI’s Forecast Scenario

Chapter 7 - Competitive Landscape

Profiles: Leading Foreign Companies

GlaxoSmithKline

Sanofi-Aventis

Pfizer

Bayer

Roche

Profiles: Leading Indigenous Manufacturers

Aspen Pharmacare

Adcock Ingram

Chapter 8 - BMI Forecast Modelling

How We Generate Our Industry Forecasts

Technical Process

Pharmaceutical Industry

Sources

Chapter 9 - Appendix: Regional Demographic Data

The Long View: Data Over The Economic Cycle (2000-2007)

Population

Household Spending Per Capita, US$

Private Consumption Per Capita, US$ PPP

Market Size, GDP, US$bn

Chapter 10 - Country Snapshot: South Africa Demographic Data

Section 1: Population

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption And Stratification

Table: Wages Per Year

Competitive Landscape for Middle East & Africa Pharmaceuticals and Healthcare: Sample of Companies Ranked

[TOP]

Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.

Network of Middle Eastern and African Pharmaceutical & Healthcare Sources

[TOP]

BMI's Middle Eastern & African Pharmaceutical & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceutical & healthcare industry associations, chambers of commerce and company reports. Information sources include:

 

Read about our other Pharmaceuticals & Healthcare Reports

Asia Europe Middle East & Africa Latin America
UK
UAE
[top]

 

Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research

Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK

BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.

Country Risk Analysis and Forecasts
BMI
has for 24 years specialised in political risk analysis, financial markets analysis, and macroeconomic forecasts on 175 global markets.

Industry Intelligence and Market Research
BMI's industry research covers Automotives; Banking; Chemicals; Defence & Security; Food & Drink; Freight Transport; Information Technology; Infrastructure; Insurance; Mining; Oil & Gas; Petrochemicals; Pharmaceuticals & Healthcare; Power; Telecommunications, and Tourism.

Company Research
BMI maintains a fully-researched 55,000-site database of multinational company subsidiaries located across global markets.